Shorter course of treatment may provide better outcome for intermediate-risk prostate cancer

Researchers found that the one-month duration HRT, was associated with a significant improvement in prostate cancer recurrence compared to the two-month duration CRT and therefore would be reasonable to consider in men with intermediate risk prostate cancer who do not have risk factors that could predispose the patient to bladder side effects several years after the treatment is complete.